{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T14:18:01Z","timestamp":1769264281544,"version":"3.49.0"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T00:00:00Z","timestamp":1612310400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2021,4]]},"DOI":"10.1007\/s00705-021-04969-4","type":"journal-article","created":{"date-parts":[[2021,2,3]],"date-time":"2021-02-03T12:06:07Z","timestamp":1612353967000},"page":"1071-1081","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Treatment of hepatitis C virus infection with direct-acting antivirals plus ribavirin eliminates viral RNA from peripheral blood mononuclear cells and reduces virologic relapse in diverse hepatic parenchymal changes"],"prefix":"10.1007","volume":"166","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3601-6907","authenticated-orcid":false,"given":"Mohamed Darwish Ahmed","family":"Abd Alla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reham M.","family":"Dawood","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hassan Abd EL-Hafeth","family":"Rashed","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Galal","family":"Farrag","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Islam Abdelmawla Emran","family":"Ammar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mohamed Mahmoud Abdel-Halim","family":"Mahmoud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ghada M.","family":"Salum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ahmed Mohamed Abdulhamid","family":"Altanbouly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mai A.","family":"El Meguid","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mostafa K. El","family":"Awady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,3]]},"reference":[{"issue":"5","key":"4969_CR1","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.jhep.2014.10.044","volume":"62","author":"PJ Ruane","year":"2015","unstructured":"Ruane PJ, Ain D, Stryker R, Meshrekey R et al (2015) Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol 62(5):1040\u20131046","journal-title":"J Hepatol"},{"issue":"3","key":"4969_CR2","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.jhep.2015.04.023","volume":"63","author":"W Doss","year":"2015","unstructured":"Doss W, Shiha G, Hassany M, Soliman R et al (2015) Sofosbuvir plus ribavirin for treating Egyptian patients with hepatitis C genotype 4. J Hepatol 63(3):581\u2013585","journal-title":"J Hepatol"},{"issue":"4","key":"4969_CR3","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1111\/liv.13266","volume":"37","author":"R Eletreby","year":"2017","unstructured":"Eletreby R, Elakel W, Said M, El Kassas M et al (2017) Real life Egyptian experience of efficacy and safety of Simeprevir\/Sofosbuvir therapy in 6211 chronic HCV genotype IV infected patients. Liver Int 37(4):534\u2013541","journal-title":"Liver Int"},{"key":"4969_CR4","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1111\/liv.13319","volume":"37","author":"R Eletreby","year":"2017","unstructured":"Eletreby R, Elakel W, El Raziky M, Esmat G (2017) Response to Real life Egyptian experience of efficacy\/safety of Simeprevir\\Sofosbuvir in HCV genotype IV. Liver Int 37:766\u2013766","journal-title":"Liver Int"},{"issue":"6","key":"4969_CR5","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1136\/gutjnl-2014-307498","volume":"64","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Hirschfield GM, Ghesquiere W, Sievert W et al (2015) Daclatasvir plus peginterferon alfa and ribavirin for treatment-naive chronic hepatitis C genotype 1 or 4 infection: a randomised study. Gut 64(6):948\u2013956","journal-title":"Gut"},{"issue":"5","key":"4969_CR6","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jhep.2014.12.031","volume":"62","author":"C Moreno","year":"2015","unstructured":"Moreno C, Hezode C, Marcellin P, Bourgeois S et al (2015) Efficacy and safety of simeprevir with PegIFN\/ribavirin in naive or experienced patients infected with chronic HCV genotype 4. J Hepatol 62(5):1047\u20131055","journal-title":"J Hepatol"},{"issue":"10","key":"4969_CR7","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/S1473-3099(17)30496-6","volume":"17","author":"X Forns","year":"2017","unstructured":"Forns X, Lee SS, Valdes J, Lens S, Ghalib R, Aguilar H et al (2017) Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis 17(10):1062\u20131068","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"4969_CR8","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.cgh.2017.09.027","volume":"16","author":"T Asselah","year":"2018","unstructured":"Asselah T, Kowdley KV, Zadeikis N et al (2018) Efficacy of glecaprevir\/pibrentasvir for 8 or 12 weeks in patients with HCV genotype 2,4,5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol 16(3):417\u2013426","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"27","key":"4969_CR9","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1056\/NEJMoa1512610","volume":"373","author":"JJ Feld","year":"2015","unstructured":"Feld JJ, Jacobson IM, H\u00e9zode C, Asselah T et al (2015) Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 373(27):2599\u20132607","journal-title":"N Engl J Med"},{"issue":"2","key":"4969_CR10","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jhep.2017.03.039","volume":"67","author":"PY Kwo","year":"2017","unstructured":"Kwo PY, Poordad F, Asatryan A, Wang S, Wyles DL et al (2017) Glecaprevir and pibrentasvir yield high response rates in patients with HCV genotype 1\u20136 without cirrhosis. J Hepatol 67(2):263\u2013271","journal-title":"J Hepatol"},{"issue":"9","key":"4969_CR11","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1111\/liv.13727","volume":"38","author":"T Asselah","year":"2018","unstructured":"Asselah T, Reesink H, Gerstoft J, de Ledinghen V et al (2018) Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int 38(9):1583\u20131591","journal-title":"Liver Int"},{"issue":"11","key":"4969_CR12","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1080\/17512433.2016.1233813","volume":"9","author":"M El Kassas","year":"2016","unstructured":"El Kassas M, Elbaz T, Abd El Latif Y, Esmat G (2016) Elbasvir and grazoprevir for chronic hepatitis C genotypes 1 and 4. Expert Rev Clin Pharmacol 9(11):1413\u20131421","journal-title":"Expert Rev Clin Pharmacol"},{"issue":"9","key":"4969_CR13","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1016\/S1473-3099(15)00157-7","volume":"15","author":"A Kohli","year":"2015","unstructured":"Kohli A, Kapoor R, Sims Z, Nelson A et al (2015) Ledipasvir and sofosbuvir for hepatitis C genotype 4: a proof-of-concept, single-centre, open-label phase 2a cohort study. Lancet Infect Dis 15(9):1049\u20131054","journal-title":"Lancet Infect Dis"},{"issue":"4","key":"4969_CR14","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/hep.28706","volume":"64","author":"A Abergel","year":"2016","unstructured":"Abergel A, Metivier S, Samuel D, Jiang D et al (2016) Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology 64(4):1049\u20131056","journal-title":"Hepatology"},{"issue":"1","key":"4969_CR15","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/S2468-1253(16)30002-4","volume":"1","author":"I Waked","year":"2016","unstructured":"Waked I, Shiha G, Qaqish RB, Esmat G et al (2016) Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial. Lancet Gastroenterol Hepatol 1(1):36\u201344","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"9986","key":"4969_CR16","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1016\/S0140-6736(15)60159-3","volume":"385","author":"C H\u00e9zode","year":"2015","unstructured":"H\u00e9zode C, Asselah T, Reddy KR, Hassanein T et al (2015) Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet 385(9986):2502\u20132509","journal-title":"Lancet"},{"issue":"1","key":"4969_CR17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/liv.13212","volume":"37","author":"JJ Feld","year":"2017","unstructured":"Feld JJ, Jacobson IM, Sulkowski MS, Poordad F, Tatsch F, Pawlotsky JM (2017) Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection. Liver Int 37(1):5\u201318","journal-title":"Liver Int"},{"issue":"1","key":"4969_CR18","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1053\/j.gastro.2014.09.023","volume":"148","author":"MP Curry","year":"2015","unstructured":"Curry MP, Forns X, Chung RT, Terrault NA et al (2015) Sofosbuvir and ribavirin prevent recurrence of HCV infection after liver transplantation: an open-label study. Gastroenterology 148(1):100\u2013107","journal-title":"Gastroenterology"},{"issue":"3","key":"4969_CR19","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1053\/j.gastro.2015.05.010","volume":"149","author":"M Charlton","year":"2015","unstructured":"Charlton M, Everson GT, Flamm SL, Kumar P et al (2015) Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology 149(3):649\u2013659","journal-title":"Gastroenterology"},{"key":"4969_CR20","doi-asserted-by":"crossref","first-page":"S276","DOI":"10.1016\/S0168-8278(18)30769-4","volume":"68","author":"G Soliman","year":"2018","unstructured":"Soliman G, Negm MS, Elzalabany M, Malik AA et al (2018) Is treatment of hepatitis C with controlled generic direct acting antiviral drugs effective? An Egyptian experience. J Hepatol 68:S276","journal-title":"J Hepatol"},{"issue":"1","key":"4969_CR21","doi-asserted-by":"crossref","first-page":"e000112","DOI":"10.1136\/bmjgast-2016-000112","volume":"3","author":"E Hathorn","year":"2016","unstructured":"Hathorn E, Elsharkawy AM (2016) Management of hepatitis C genotype 4 in the directly acting antivirals era. BMJ Open Gastroenterol 3(1):e000112","journal-title":"BMJ Open Gastroenterol"},{"key":"4969_CR22","first-page":"143","volume":"1","author":"H Salama","year":"2016","unstructured":"Salama H, Zekri A, Medhat E et al (2016) Sofosbuvir plus daclatasvir with fixed versus weight adjusted dose of ribavirin for treatment of HCV genotype 4 among Egyptian patients. EC Gastroenterol Dig Syst 1:143\u2013153","journal-title":"EC Gastroenterol Dig Syst"},{"issue":"4","key":"4969_CR23","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ajme.2013.05.004","volume":"50","author":"AF Hanno","year":"2014","unstructured":"Hanno AF, Mohiedeen KM, Alshayeb AF, Deghedy A (2014) HCV RNA in peripheral blood mononuclear cells (PBMCs) as a predictor of the response to antiviral therapy in chronic hepatitis C. Alex J Med 50(4):317\u2013322","journal-title":"Alex J Med"},{"key":"4969_CR24","doi-asserted-by":"crossref","first-page":"1554","DOI":"10.1002\/jmv.21866","volume":"82","author":"I Castillo","year":"2010","unstructured":"Castillo I, Bartolom\u00e9 J, Quiroga JA, Barril G, Carre\u00f1o V (2010) Diagnosis of occult hepatitis C without the need for a liver biopsy. J Med Virol 82:1554\u20131559","journal-title":"J Med Virol"},{"issue":"1","key":"4969_CR25","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1086\/380202","volume":"189","author":"I Castillo","year":"2004","unstructured":"Castillo I, Pardo M, Bartolom\u00e9 J et al (2004) Occult hepatitis C virus infection in patients in whom the etiology of persistently abnormal results of liver-function tests is unknown. J Infect Dis 189(1):7\u201314","journal-title":"J Infect Dis"},{"key":"4969_CR26","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2017.00034","volume":"5","author":"MDA Abd Alla","year":"2017","unstructured":"Abd Alla MDA, El Awady MK (2017) Hepatitis C virus RNA strands detection in peripheral blood mononuclear cells legitimizes virus eradication in negative serum PCR na\u00efve and post-treatment patients. J Clin Transl Hepatol 5:1\u20138","journal-title":"J Clin Transl Hepatol"},{"key":"4969_CR27","first-page":"319","volume":"5","author":"MDA Abd Alla","year":"2017","unstructured":"Abd Alla MDA, Elibiary SA, Wu GY, El-Awady MK (2017) Occult HCV infection (OCI) diagnosis in cirrhotic and non-cirrhotic na\u00efve patients by intra-PBMC nested viral rNA PCR. J Clin Transl Hepatol 5:319\u2013326","journal-title":"J Clin Transl Hepatol"},{"issue":"10","key":"4969_CR28","first-page":"2765","volume":"163","author":"MDA Abd Alla","year":"2018","unstructured":"Abd Alla MDA, El Awady MK, Dawood RM, Elhawary MA et al (2018) Hepatitis C virus serologic relapse after treatment with direct-acting antivirals is dependent on viral RNA levels in peripheral blood mononuclear cells and the grade of liver cirrhosis. Adv Virol 163(10):2765\u20132774","journal-title":"Adv Virol"},{"key":"4969_CR29","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1053\/j.gastro.2016.04.003","volume":"151","author":"JM Pawlosky","year":"2016","unstructured":"Pawlosky JM (2016) Hepatitis C virus resistance to direct-acting antiviral drugs in interferon free regimens. Gastroenterology 151:70\u201386","journal-title":"Gastroenterology"},{"issue":"7","key":"4969_CR30","doi-asserted-by":"publisher","first-page":"e101760","DOI":"10.1371\/journal.pone.0101760","volume":"9","author":"S Corchado","year":"2014","unstructured":"Corchado S, L\u00f3pez CLF, Rivero JA et al (2014) Liver fibrosis, host genetic and hepatitis C virus related parameters as predictive factors of response to therapy against hepatitis C virus in HIV\/HCV coinfected patients. PLoS One 9(7):e101760. https:\/\/doi.org\/10.1371\/journal.pone.0101760","journal-title":"PLoS One"},{"key":"4969_CR31","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1002\/hep.24262","volume":"53","author":"JM Pawlosky","year":"2011","unstructured":"Pawlosky JM (2011) Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 53:1742\u20131751","journal-title":"Hepatology"},{"issue":"6","key":"4969_CR32","doi-asserted-by":"crossref","first-page":"1138","DOI":"10.1016\/j.jhep.2017.01.028","volume":"66","author":"JL Calleja","year":"2017","unstructured":"Calleja JL, CrespoJ RD et al (2017) Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in Hepatitis C Virus genotype 1 infection: results from a Spanish real-world cohort. J of hepatology 66(6):1138\u20131148","journal-title":"J of hepatology"},{"issue":"4","key":"4969_CR33","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.cgh.2014.12.014","volume":"13","author":"NH Afdhal","year":"2015","unstructured":"Afdhal NH, BaconBR PK, Lawitz EJ et al (2015) Accuracy of fibroscan, compared with histology, in analysis of liver fibrosis in patients with hepatitis B or C: a United States multicenter study. Clin Gastroenterol Hepatol 13(4):772\u2013779","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"4969_CR34","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1002\/hep.20935","volume":"42","author":"P Cal\u00e8s","year":"2005","unstructured":"Cal\u00e8s P, Oberti F, Michalak S, Hubert-Fouchard I et al (2005) A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology 42(6):1373\u20131381","journal-title":"Hepatology"},{"key":"4969_CR35","doi-asserted-by":"crossref","first-page":"2156","DOI":"10.1023\/A:1018888021118","volume":"43","author":"DW Reedy","year":"1998","unstructured":"Reedy DW, Loo AT, Levine RA (1998) AST\/ALT ratio \u2265 1 is not diagnostic of cirrhosis in patients with chronic hepatitis C. Dig Dis Sci 43:2156\u20132159","journal-title":"Dig Dis Sci"},{"key":"4969_CR36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.21608\/zumj.2017.41211","volume":"21","author":"EA Wahab","year":"2017","unstructured":"Wahab EA, Fathy T, Saber S, Ahmad HS (2017) Hepatic elastography and fib-4 score versus liver biopsy for assessment of liver fibrosis in chronic Hcv patients. Zagazig Univ Med J 21:1\u201311","journal-title":"Zagazig Univ Med J"},{"key":"4969_CR37","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/0003-2697(87)90021-2","volume":"162","author":"P Chomczy\u0144ski","year":"1987","unstructured":"Chomczy\u0144ski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinum thiocyanate-phenol-chlotoform extraction. Anal Biochem 162:156\u2013159","journal-title":"Anal Biochem"},{"key":"4969_CR38","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1046\/j.1440-1746.2003.02919.x","volume":"18","author":"MK El-Awady","year":"2003","unstructured":"El-Awady MK, Abdel Rahman MM, Ismail SM, Amr KS, Omran M et al (2003) Prediction of relapse after interferon therapy in hepatitis C virus-infected patients by the use of triple assay. J Gastroenterol Hepatol 18:68\u20137339","journal-title":"J Gastroenterol Hepatol"},{"key":"4969_CR39","doi-asserted-by":"crossref","first-page":"323","DOI":"10.21608\/jesp.2017.77783","volume":"47","author":"AA Elzahaby","year":"2017","unstructured":"Elzahaby AA, Soliman GM, Korany MA et al (2017) Association between post treatment existence Of HCV\/RNA positive strand and\/or negative strand in the PBMCs and HCV relapse. J Egypt Soc Parasitol 47:323\u2013330","journal-title":"J Egypt Soc Parasitol"},{"issue":"1","key":"4969_CR40","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1186\/1743-422X-10-346","volume":"10","author":"A Pawe\u0142czyk","year":"2013","unstructured":"Pawe\u0142czyk A, Kubisa N, Jab\u0142o\u0144ska J et al (2013) Detection of hepatitis C virus (HCV) negative strand RNA and NS3 protein in peripheral blood mononuclear cells (PBMC): CD3+, CD14+ and CD19+. Virol J 10(1):346. https:\/\/doi.org\/10.1186\/1743-422X-10-346","journal-title":"Virol J"},{"issue":"1\u20132","key":"4969_CR41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0009-8981(99)00007-8","volume":"283","author":"MK El-Awady","year":"1999","unstructured":"El-Awady MK, Ismail SM, El-Sagheer M et al (1999) Assay for hepatitis C virus in peripheral blood mononuclear cells enhances sensitivity of diagnosis and monitoring of HCV-associated hepatitis. Clin Chim Acta 283(1\u20132):1\u201314","journal-title":"Clin Chim Acta"},{"issue":"2","key":"4969_CR42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.14218\/JCTH.2017.00077","volume":"6","author":"MDA Abd Alla","year":"2018","unstructured":"Abd Alla MDA, Elibiary SA, Elshaboury RH et al (2018) HCV therapy follow-up fractionation (CTF2) by intra-PBMC nested RNA PCR recognizes early virologic response and relapse. J Clin Trans Hepatol 6(2):1\u20138","journal-title":"J Clin Trans Hepatol"},{"issue":"2","key":"4969_CR43","doi-asserted-by":"crossref","first-page":"197","DOI":"10.4103\/AZMJ.AZMJ_22_18","volume":"16","author":"MDA Abd Alla","year":"2018","unstructured":"Abd Alla MDA, Gomaa AA, Farrag GAA et al (2018) Retrospective study of hepatitis c virus relapse after treatment with sofosbuvir and daclatasvir with or without ribavirin. Al-Azhar Assiut Med J 16(2):197\u2013204","journal-title":"Al-Azhar Assiut Med J"},{"issue":"1","key":"4969_CR44","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1111\/jgh.14815","volume":"35","author":"CF Huang","year":"2020","unstructured":"Huang CF, Yeh ML, Huang CI et al (2020) Ribavirin facilitates early viral kinetics in chronic hepatitis C patients receiving daclatasvir\/asunaprevir. J Gastroenterol Hepatol 35(1):151\u2013156","journal-title":"J Gastroenterol Hepatol"},{"key":"4969_CR45","first-page":"209","volume":"5","author":"A Elsharkawy","year":"2017","unstructured":"Elsharkawy A, Hashem M, Fouad R, Negm M et al (2017) Safety and efficacy of the generic products of sofosbuvir and daclatasvir in treatment of HCV genotype 4 Egyptian patients. Merit Res J Med Med Sci 5:209\u2013213","journal-title":"Merit Res J Med Med Sci"},{"key":"4969_CR46","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1111\/apt.13541","volume":"43","author":"QL Zeng","year":"2016","unstructured":"Zeng QL, Li CX, Zhang DW et al (2016) safety and efficacy of sofosbuvir plus daclatasvir with ribavirin for 12 weeks in Chinese treatment-experienced cirrhotic genotype 1b patients with HCV. Aliment Pharm Ther 43:842\u2013843","journal-title":"Aliment Pharm Ther"},{"issue":"4","key":"4969_CR47","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1002\/hep.27726","volume":"61","author":"DR Nelson","year":"2015","unstructured":"Nelson DR, Cooper JN, Lalezari JP, Lawitz E et al (2015) All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology 61(4):1127\u20131135","journal-title":"Hepatology"},{"issue":"3","key":"4969_CR48","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1053\/j.gastro.2016.05.049","volume":"151","author":"GN Ioannou","year":"2016","unstructured":"Ioannou GN, Beste LA, Chang MF et al (2016) Effectiveness of sofosbuvir, ledipasvir\/sofosbuvir, or paritaprevir\/ritonavir\/ombitasvir and dasabuvir regimens for treatment of patients with hepatitis C in the Veterans Affairs National Health Care System. Gastroenterology 151(3):457\u2013471","journal-title":"Gastroenterology"},{"issue":"7","key":"4969_CR49","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1111\/apt.13095","volume":"41","author":"RK Sterling","year":"2015","unstructured":"Sterling RK, Kuo A, Rustgi VK et al (2015) Virological outcomes and treatment algorithms utilisation in observational study of patients with chronic hepatitis C treated with boceprevir or telaprevir. Aliment Pharm Ther 41(7):671\u2013685","journal-title":"Aliment Pharm Ther"},{"issue":"1","key":"4969_CR50","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s15010-016-0962-3","volume":"45","author":"L Boglione","year":"2017","unstructured":"Boglione L, Pinna SM, Cardellino CS et al (2017) Treatment with daclatasvir and sofosbuvir for 24 weeks without ribavirin in cirrhotic patients who failed first-generation protease inhibitors. Infection 45(1):103\u2013106","journal-title":"Infection"},{"issue":"1","key":"4969_CR51","doi-asserted-by":"publisher","first-page":"e44564","DOI":"10.5812\/hepatmon.44564","volume":"17","author":"S Merat","year":"2017","unstructured":"Merat S, Sharifi AH, Haj-Sheykholeslami A et al (2017) The efficacy of 12 weeks of sofosbuvir, daclatasvir, and ribavirin in treating hepatitis C patients with cirrhosis, genotypes 1 and 3. Hepat Mon 17(1):e44564. https:\/\/doi.org\/10.5812\/hepatmon.44564","journal-title":"Hepat Mon"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-021-04969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00705-021-04969-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-021-04969-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,23]],"date-time":"2024-08-23T13:56:11Z","timestamp":1724421371000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00705-021-04969-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,3]]},"references-count":51,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["4969"],"URL":"https:\/\/doi.org\/10.1007\/s00705-021-04969-4","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,3]]},"assertion":[{"value":"26 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors have no conflicts of interest related to this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the current study that involved human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and animal rights"}},{"value":"Informed consent was obtained from all individual participants included in the current study. This article does not contain any studies with animals performed by any of the authors.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"Trop.Med._13Med.Research_Inf.GIT.Liv.Dis._0000013.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval certificate registration number"}}]}}